|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
|
US20060280774A1
(en)
*
|
1995-06-02 |
2006-12-14 |
Allergan, Inc. |
Compositions and methods for treating glaucoma
|
|
US6329369B1
(en)
*
|
1997-12-04 |
2001-12-11 |
Allergan Sales, Inc. |
Methods of treating pain and other conditions
|
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
|
EP1339438B1
(en)
*
|
2000-11-29 |
2005-10-19 |
Allergan Inc. |
Preventing transplant rejection in the eye
|
|
US7323485B2
(en)
*
|
2002-05-21 |
2008-01-29 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
|
US7091232B2
(en)
*
|
2002-05-21 |
2006-08-15 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
|
US7358269B2
(en)
*
|
2002-05-21 |
2008-04-15 |
Allergan, Inc. |
2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
|
|
US7276522B2
(en)
*
|
2002-05-21 |
2007-10-02 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
|
US20050244469A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
|
WO2006036497A2
(en)
*
|
2004-09-24 |
2006-04-06 |
Allergan, Inc. |
4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
|
|
WO2006036507A1
(en)
|
2004-09-24 |
2006-04-06 |
Allergan, Inc. |
4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
|
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
WO2008014299A2
(en)
*
|
2006-07-27 |
2008-01-31 |
Allergan, Inc. |
Use of an alpha2-agonist composition for the treatment of hyperlipidemia
|
|
US20080153825A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
|
|
EP2428207A1
(en)
|
2006-12-22 |
2012-03-14 |
Allergan, Inc. |
Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
|
US20080153874A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
|
US20080153927A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
|
US20080153881A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
|
US20120083508A1
(en)
|
2006-12-22 |
2012-04-05 |
Allergan, Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
|
US8455548B2
(en)
*
|
2007-10-18 |
2013-06-04 |
Allergan, Inc. |
Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
|
|
US20100216857A1
(en)
*
|
2007-10-18 |
2010-08-26 |
Luhrs Lauren M B |
Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
|
|
WO2009052075A2
(en)
*
|
2007-10-18 |
2009-04-23 |
Allergan, Inc. |
Method of treating motor disorders with alpha-2b adrenergic receptor agonists
|
|
US20120190719A1
(en)
|
2009-08-26 |
2012-07-26 |
Allergan, Inc. |
Methods of treating motor disorders with alpha-2b andrenergic receptor agonists
|
|
PL2605771T3
(pl)
|
2010-08-16 |
2018-10-31 |
Allergan, Inc. |
Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
|
|
CN104837850B
(zh)
*
|
2013-06-04 |
2018-09-14 |
塞勒创尼克斯公司 |
腈-取代的硅烷和电解质组合物和包含它们的电化学装置
|
|
CN105531252B
(zh)
|
2013-09-12 |
2018-01-09 |
信越化学工业株式会社 |
用于制备β‑环薰衣草醛及其衍生物的方法
|
|
EP3045442A4
(en)
*
|
2013-09-12 |
2017-04-05 |
Shin-Etsu Chemical Co., Ltd. |
Method for producing cyclolavandulol and derivative thereof
|
|
RU2552529C1
(ru)
*
|
2013-11-29 |
2015-06-10 |
Федеральное государственное бюджетное учреждение "Медицинский радиологический научный центр" Министерства здравоохранения Российской Федерации (ФГБУ МРНЦ Минздрава России) |
Вазопрессорное средство
|
|
US12440821B2
(en)
|
2021-12-13 |
2025-10-14 |
Saudi Arabian Oil Company |
Method for tracing subterranean formations with oil-soluble organic molecular tracers and extracting them of from oil phases
|
|
US11725139B2
(en)
|
2021-12-13 |
2023-08-15 |
Saudi Arabian Oil Company |
Manipulating hydrophilicity of conventional dye molecules for water tracer applications
|
|
US12188350B2
(en)
*
|
2022-06-08 |
2025-01-07 |
Saudi Arabian Oil Company |
Fluorescent dye oil tracer compositions
|